{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Immunovant, Inc. "},"Symbol":{"label":"Symbol","value":"IMVT"},"Address":{"label":"Address","value":"320 WEST 37TH STREET,6TH FLOOR, NEW YORK, New York, 10018, United States"},"Phone":{"label":"Phone","value":"+1 917 580-3099"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes IMVT-1401 targets the neonatal Fc receptor (FcRn)."},"CompanyUrl":{"label":"Company Url","value":"https://www.immunovant.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anthony Kidwell","title":"Vice President-Information Technology"},{"name":"Ian Gourley","title":"Vice President-Clinical Development"},{"name":"Jay Stout","title":"Chief Technology Officer"},{"name":"Jennifer M. Moseley","title":"Vice President-Clinical Operations"},{"name":"Maria Alba","title":"Vice President-Clinical Development"},{"name":"Michael Geffner","title":"Chief Medical Officer"},{"name":"Paola Mina Osorio","title":"Vice President-Medical Affairs"},{"name":"Peter Salzmann","title":"Chief Executive Officer & Director"},{"name":"Ranjit Deshmukh","title":"Vice President-CMC & Technical Operations"},{"name":"Sheetal Patel","title":"Vice President-Clinical Dvelopment"},{"name":"William L. Macias","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}